|
| Monday, 9 November 2020, 08:08 HKT/SGT | |
| |  | |
Source: Eisai | |
|
|
|
|
| - The Content Presented at the 13th Clinical Trials on Alzheimer's Disease (CTAD) Conference - |
TOKYO, Nov 9, 2020 - (JCN Newswire) - Sysmex Corporation and Eisai Co., Ltd. announced that the most recent data from the project to develop a method of diagnosing Alzheimer's disease (AD) using blood plasma was presented at the 13th Clinical Trials on Alzheimer's Disease (CTAD) conference, held virtually from November 4 to 7, 2020. Sysmex demonstrated on behalf of the two companies the performance of the amyloid beta (Abeta) in plasma measured on Sysmex's HISCLTM fully automated immunoassay analyzers in predicting amyloid pathology as defined by amyloid positron emission tomography (PET) imaging on the centiloid scale.(1)
The total number of those living with dementia across the world is projected to reach 82 million in 2030 and 152 million in 2050, with the total global societal cost of dementia stemming from direct medical and social care costs and lower productivity being estimated to reach 2 trillion USD in 2030.(6) In Japan, the number of those with dementia is thought to have reached approximately 4.62 million in 2012 and is projected to grow to 7.30 million in 20257, with the total societal cost of this disease is estimated to be equivalent to 4.1%8 of the gross domestic product (GDP) in 2025 (25.8 trillion yen9). Of these sufferers, those living with AD are thought to account for more than 60% of those living with dementia.(7)
It is conceivable that AD is a disease that results in synaptic dysfunction and neuronal cell death due to tau deposition in neurons triggered by Abeta aggregation on the outside of neurons. These brain changes cause cognitive impairment and psychological and behavioral symptoms, suggesting that the Abeta aggregation and accumulation inside the brain is caused by AD before the presence of cognitive impairment appears, thus, it is believed that early diagnosis and early intervention is more effective in therapies targeting Abeta. Currently, amyloid PET and Abeta ratio in cerebrospinal fluid (CSF) are used for detecting amyloid aggregates in the brain, but this puts a significant burden on patients in terms of access, costs, and their physical wellbeing.(10)
Sysmex and Eisai are working to create new diagnostic technologies for the prevention and treatment of dementia. Accordingly, the overarching aim is to contribute to the advancement of healthcare and improve the quality of life for those living with the disease and their families.
Terminology
(1) A standardization scale for integration analysis of PET SUVR values as measured by different amyloid PET imaging probes.
(2) Trained doctors qualitatively distinguish amyloid PET positive from amyloid negative subjects by visually reading images.
(3) Klunk WE et al, Alzheimer's Dementia (2014)
(4) Assesses how correlated two sets of data are based on two quantitative data distributions.
For the purpose of this analysis, Spearman's rank correlation coefficient (rs), which is a
correlation index as determined by the rankings of the two variables, was calculated.
(5) Schindler SE et al, Neurology (2019)
(6) World Alzheimer Report 2018
(7) Promotion of Comprehensive Measures against Dementia, Ministry of Health, Labour and
Welfare
(8) Study on Economic Impact of Dementia in Japan, 2014 Health Labour Sciences Research
Grant Annual Report
(9) Estimated by Sysmex based on Japan's Medium-term Economic Outlook (February 2018),
Daiwa Institute of Research
(10) Abeta is a peptide made of amino-acid residues removed from amyloid precursor protein. Many of them are Abeta1-40, which is comprised of 40-residues, and the Abeta1-40 level does not fluctuate significantly as AD progresses. Comprised of 42-residues, Abeta1-42, on the other hand, is highly cohesive and decreases in cerebrospinal fluid (CSF) from the early stages of AD. It is believed that Abeta's absolute values show individual and intrinsic variability but that the plasma Abeta1-42/Abeta1-40 ratio remains unchanged. It has also been reported that the plasma Abeta1-42/Abeta1-40 ratio in CSF shows a high correlation with amyloid PET.
About the collaboration between Sysmex and Eisai
In February 2016, Sysmex and Eisai signed a comprehensive non-exclusive agreement aimed at the development of new diagnostic tests in the field of dementia. By leveraging each other's technologies and knowledge, the objective has been to discover next-generation diagnostic reagents that will enable early diagnosis of dementia, selection of the most appropriate treatment options, and regular monitoring of the effects of such treatments. At the 12th CTAD held in December 2019, the two companies reported on the performance of the plasma Abeta ratio measured on a fully automated immunoassay system HISCL in predicting the amyloid PET scan results (sensitivity: 73%, specificity: 71% [AUC = 0.74]), thus demonstrating the potential to predict amyloid pathology in the brain using the plasma Abeta ratio.* This finding was expected to lead to the development of a simple method of diagnosing Alzheimer's disease using blood.
*https://www.sysmex.co.jp/en/news/2019/191209.html https://www.eisai.com/news/2019/news201990.html
Topic: Press release summary
Source: Eisai
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| Eisai |
| Nov 20, 2024 10:51 HKT/SGT |
|
Rozebalamin for Injection 25mg (Mecobalamin) for Amyotrophic Lateral Sclerosis Launched in Japan |
| Nov 20, 2024 09:24 HKT/SGT |
|
Anticancer Agent "TASFYGO Tablets 35mg" (Tasurgratinib Succinate) Launches in Japan for Biliary Tract Cancer with FGFR2 Gene Fusion or Rearrangements |
| Nov 15, 2024 16:33 HKT/SGT |
|
Nationwide TV Commercial Launched in Japan to Raise Awareness About MCI (Mild Cognitive Impairment) |
| Nov 15, 2024 13:31 HKT/SGT |
|
Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease |
| Nov 5, 2024 10:35 HKT/SGT |
|
Eisai's Corporate Venture Capital Subsidiary, Eisai Innovation, Inc., Selected for AMED's 'Strengthening Program for Pharmaceutical Startup Ecosystem" |
| Nov 1, 2024 12:56 HKT/SGT |
|
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status |
| Oct 31, 2024 12:56 HKT/SGT |
|
Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer's Disease (CTAD) Conference |
| Oct 31, 2024 10:33 HKT/SGT |
|
Eisai Presents Latest Clinical Findings Suggesting Inhibition of Tau Propagation by Anti-MTBR Tau Antibody E2814 at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD) |
| Oct 17, 2024 19:01 HKT/SGT |
|
A Joint Regional Cohort Study by Shimadzu, Eisai, Oita University, and Usuki City Medical Association |
| Oct 17, 2024 14:59 HKT/SGT |
|
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in Australia |
| More news >> |
 |
|
|
|
